SHORT REPORT

The Eagle effect in the *Wolbachia*-worm symbiosis

Christina A. Bulman1, Laura Chappell2, Emma Gunderson1, Ian Vogel1, Brenda Beerntsen3, Barton E. Slatko4, William Sullivan2 and Judy A. Sakanari1*

Abstract

**Background:** Onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) are two human neglected tropical diseases that cause major disabilities. Mass administration of drugs targeting the microfilarial stage has reduced transmission and eliminated these diseases in several countries but a macrofilaricidal drug that kills or sterilizes the adult worms is critically needed to eradicate the diseases. The causative agents of onchocerciasis and lymphatic filariasis are filarial worms that harbor the endosymbiotic bacterium *Wolbachia*. Because filarial worms depend on *Wolbachia* for reproduction and survival, drugs targeting *Wolbachia* hold great promise as a means to eliminate these diseases.

**Methods:** To better understand the relationship between *Wolbachia* and its worm host, adult *Brugia pahangi* were exposed to varying concentrations of doxycycline, minocycline, tetracycline and rifampicin in vitro and assessed for *Wolbachia* numbers and worm motility. Worm motility was monitored using the Worminator system, and *Wolbachia* titers were assessed by qPCR of the single copy gene *wsp* from *Wolbachia* and *gst* from *Brugia* to calculate IC50s and in time course experiments. Confocal microscopy was also used to quantify *Wolbachia* located at the distal tip region of worm ovaries to assess the effects of antibiotic treatment in this region of the worm where *Wolbachia* are transmitted vertically to the microfilarial stage.

**Results:** Worms treated with higher concentrations of antibiotics had higher *Wolbachia* titers, i.e. as antibiotic concentrations increased there was a corresponding increase in *Wolbachia* titers. As the concentration of antibiotic increased, worms stopped moving and never recovered despite maintaining *Wolbachia* titers comparable to controls. Thus, worms were rendered moribund by the higher concentrations of antibiotics but *Wolbachia* persisted suggesting that these antibiotics may act directly on the worms at high concentration. Surprisingly, in contrast to these results, antibiotics given at low concentrations reduced *Wolbachia* titers.

**Conclusion:** *Wolbachia* in *B. pahangi* display a counterintuitive dose response known as the “Eagle effect.” This effect in *Wolbachia* suggests a common underlying mechanism that allows diverse bacterial and fungal species to persist despite exposure to high concentrations of antimicrobial compounds. To our knowledge this is the first report of this phenomenon occurring in an intracellular endosymbiont, *Wolbachia*, in its filarial host.

**Keywords:** *Wolbachia*, Eagle effect, Endosymbiosis, Filaria

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
malayi and Brugia timori. Each of these species harbors the endosymbiotic bacterium, Wolbachia, in the hypodermal chord and female ovaries, where the endosymbiont is passed through the female germline [1]. These filarial worms depend on Wolbachia for their long-term survival and reproduction, and Wolbachia also play a role in the clinical pathology of filarial infection [2–9]. The microfilaricidal drug ivermectin, which has been successfully used in mass drug administration (MDA) programs to eliminate onchocerciasis in Central and South America [10, 11], cannot be used in Central and West Africa because of the severe adverse effects in patients co-infected with high numbers of Loa loa microfilariae [12, 13]. Loa loa, unlike Onchocerca, Wuchereria and Brugia, does not harbor Wolbachia [14, 15], thus identifying antibiotics that eliminate Wolbachia is an excellent approach to find new drugs to eliminate onchocerciasis and lymphatic filariasis [16–19].

Clinical studies have shown that doxycycline given to patients for 4–6 weeks at 100–200 mg/day was efficacious in reducing disease pathology and microfilaremia in individuals with lymphatic filariasis [20–22] and was also effective in reducing Wolbachia, disrupting worm fertility and causing adult worm death in patients infected with O. volvulus [23–26]. Although effective as an anti-Wolbachia drug, doxycycline is contraindicated during pregnancy and for young children, and the long course of treatment is not feasible for MDA because of the challenges of patient adherence [15, 27–31]. Antibiotics such as rifampicin and minocycline, as well as novel anti-Wolbachia drugs, have also shown promise in pre-clinical models of lymphatic filariasis and onchocerciasis [19, 32–37]. However, there is evidence in pre-clinical models that if insufficient anti-Wolbachia treatment is administered, Wolbachia can repopulate their host leading to recovery of filarial fecundity [35, 38, 39].

Much remains unknown about the mechanisms by which Wolbachia repopulates an antibiotic-treated filarial worm and how the filarial worm regains its reproductive output. While it is clear that Wolbachia and its filarial host are co-dependent, the mechanisms by which Wolbachia abundance influences worm viability is unknown. This information is critical for both understanding the biology of the Wolbachia-worm symbiosis and developing efficacious protocols for treating these devastating diseases. Because of the high costs and difficulties associated with animal studies, in vitro studies have provided an excellent means to study the Wolbachia/Brugia relationship. Here we tested several antibiotics, doxycycline, tetracycline, minocycline, rifampicin and two novel anti-wolbachial compounds, with adult B. pahangi females and males in vitro to determine Wolbachia titers and their effects on worm viability. Surprisingly, there was a positive correlation between antibiotic concentrations and Wolbachia titers, a phenomenon known as the “Eagle effect,” where higher concentrations of antibiotics correlate with increased titers of bacteria [40–43]. We also determined that antibiotics affected worm viability without first reducing Wolbachia titers, suggesting that these antibiotics may act directly on the worms in vitro at high concentration.

Methods

Brugia pahangi worm assays and motility assessment

Adult B. pahangi female and male worms were collected from jirds (Meriones unguiculatus) and transferred to 24-well plates with 500 µl of culture media (RPMI-1640 with 25 mM HEPES, 2.0 g/L NaHCO3, 5% heat-inactivated FBS and 1X antibiotic/antimycotic solution). To limit variability among individual female worms, only fecund female worms that released at least 50 microfilariae (mf) were used. To determine IC50s, worms were treated with a 6-point serial dilution of 100, 30, 10, 3, 1 and 0.3 µM of doxycycline hyclate (Sigma-Aldrich catalog no. D9891), minocycline hydrochloride (Sigma-Aldrich catalog no. M9511), tetracycline hydrochloride (Sigma-Aldrich catalog no. T7660) or rifampicin (Fisher Scientific catalog no. 50-213-645). To avoid precipitation of the antibiotics in media, we used a maximum concentration of 100 µM, which is below the limit of solubility in water for each of the antibiotics [44–47]. One percent DMSO (Fisher Scientific catalog no. BP231) was used for the control worms. Female worms were plated individually, and male worms were plated four per well. Worms were kept in culture in a 37 °C, 5% CO2 incubator for the duration of the assay (6 days). Worm motility was recorded on Days 0, 1, 2, 3 and 6 using the Worminator [48], and worms were collected on Day 6 for qPCR analysis.

To confirm that worm motility correlated with worm viability, B. pahangi females that had been treated with 100, 10 and 1 µM doxycycline were collected on Day 6 and assayed using a cell viability assay with thiazolyl blue tetrazolium bromide (MTT) (Sigma Aldrich catalog no. M2128) similar to ones used previously [49–51]. Worms were transferred to a 96-well plate containing 200 µl freshly prepared 0.5 mg/ml MTT in PBS per well, incubated at 37°C for 30 min and then transferred to 150 µl DMSO. After 1 h, 100 µl DMSO was transferred to a clear, flat-bottom 96-well plate, and the absorbance of formazan was read at 570 nm.

To compare the effects of two different classes of antibiotics on adult Brugia, doxycycline and tetracycline (tetracycline class of antibiotics) and rifampicin (macrocyclic antibiotic) were used in a time course experiment with male and female worms. Worms were treated with different concentrations of antibiotic and assessed over multiple time points. Female worms were treated with 100, 10 and 1 µM antibiotic, and male worms were treated with 100 and 1 µM
antibiotic. DMSO (1%) was used as the negative control. Motility was recorded on Days 0, 1, 2, 3, 5 and 6, and worms were collected for qPCR analysis on Days 1, 3 and 6.

Two novel quinazoline compounds, CBR417 and CBR490 (provided by Calibr-Scripps Research Institute, San Diego, CA) [34], were tested with B. pahangi females at 100, 10 and 1 µM. Motility was recorded on Days 0–3, and worms were collected on Day 3 for qPCR analysis. All compounds were completely soluble at all concentrations.

**Quantification of wsp and gst copy numbers from B. pahangi worms**

Treated worms were washed in PBS, frozen in a dry ice/ethanol bath and stored at −80 °C. Genomic DNA from individual female worms was extracted using the Qiagen DNeasy Blood & Tissue Kit, and genomic DNA from four male worms was extracted using the QIAamp DNA micro kit. The Wolbachia surface protein (wsp) and Brugia pahangi glutathione S-transferase (gst) primers [52] were used with the GeneCopoeia All-in-One SYBR Green qPCR mix and run in a BioRad CRX Connect thermocycler. pCR4-TOPO plasmid standards containing wsp and gst genes were used to calculate gene copy numbers from Ct values. The following primer sequences were used: 

- **gst_fwd 5’-GAGACACCTTTCGCCAAAC-3’**
- **gst_rev 5’-ATCACGGACGCTTCAGACG-3’**
- **wsp_fwd 5’-CCC TGCAAAGGCACAGTTATGG-3’**
- **wsp_rev 5’-CGA GCTCCAGCAAGAGTTATATTT-3’**

For amplification of gst, the reaction mix was heated at 95° C for 15 min, followed by 36 cycles of denaturation at 94 °C for 15 s, annealing at 55 °C for 30 s and elongation at 72 °C for 30 s. After the final cycle, melting curve analysis was conducted by heating the reaction mix at 95° C for 1 min, annealing at 55 °C for 30 s and then heating to 97 °C. For amplification of wsp, the reaction mix was heated to 95 °C for 15 min, followed by 40 cycles of denaturation at 94 °C for 10 s, annealing at 57 °C for 20 s and elongation at 72 °C for 15 s. After the final cycle, melting curve analysis was conducted by heating the reaction mix at 95 °C for 1 min, annealing at 55 °C for 30 s and then heating to 95 °C.

**Statistical analyses**

Motility data were normalized to the mean motility of DMSO control worms. Motility data (percent inhibitions) were constrained to 0 and 100% inhibition [55], and IC50s were calculated using GraphPad Prism software (Version 8.1.2). The statistical significance of reductions in motility in the time course experiment was determined using a two-way ANOVA followed by Tukey’s multiple comparisons test. Correlation coefficients (r) were determined using the CORREL function in Microsoft Excel for Mac 2011 (version 14.7.7). Correlation coefficients were determined for worm motility vs formazan production in the MTT assay, antibiotic concentration vs wsp/gst ratios of treated worms and worm motility vs wsp/gst ratios of treated worms.

**Quantification of Wolbachia in distal tip region of B. pahangi ovaries by immunofluorescence assay**

To visually confirm the effects of antibiotics on Wolbachia, worms were stained with immunofluorescent dyes and examined by confocal microscopy. As with previous studies [34, 53], quantification was limited to the distal tip region of the ovaries, which has a more consistent distribution of Wolbachia in developing oocytes than the hypodermal chords, where Wolbachia are often dispersed as regional accumulations of bacteria [1, 53, 54]. Female worms treated with 10 µM doxycycline, minocycline, tetracycline and rifampicin were frozen in drug-free culture media at −80 °C on Day 6 for immunofluorescence staining. Worms were thawed and immediately fixed in 3.2% paraformaldehyde for 25 min and then rinsed with PBST (PBS with 0.1% Triton-X100). Ovaries were dissected from the worm bodies and stained with propidium iodide (1 mg/ml diluted 100X in PBST) for 30 s, then mounted with DAPI VECTASHIELD mounting medium (Vector Labs) and imaged using an SP5 confocal microscope. Wolbachia titers were obtained by counting the number of puncta per µm² area.

**Results**

Worm motility is highly correlated to viability in MTT assay

To confirm that worm motility is indicative of worm viability, worms were analyzed using an MTT assay similar to ones used previously [49–51]. Results showed that cell viability as measured by the conversion of MTT to formazan was highly correlated with worm motility ($r = 0.889$) and that earlier cessation of worm motility was predictive of greater reduction in formazan production on Day 6 (Table 1) similar to the results found with B. malayi [49] and O. gutturosa [50].
Table 1 | Viability of female worms treated with doxycycline was highly correlated with worm motility

| Compound                | % Inhibition of motility | % Inhibition of formazan production |
|-------------------------|--------------------------|-------------------------------------|
|                         | Day 1 (%) | Day 2 (%) | Day 3 (%) | Day 4 (%) | Day 6 (%) | Day 6 (%) |
| Doxycycline (100 µM)    | 54        | 94        | 97        | 99        | 99        | 91        |
| Doxycycline (10 µM)     | 0         | 0         | 9         | 59        | 92        | 46        |
| Doxycycline (1 µM)      | 0         | 0         | 0         | 2         | 0         | 8         |

Worms treated with 100 and 10 µM doxycycline showed declining motility over time and were barely motile at 100 µM by Day 2. Viability was assessed on Day 6, as measured by formazan production in an MTT assay. The degree and duration of motility inhibition was predictive of reduced viability in the MTT assay.

Eagle effect in an endosymbiotic bacterium from a filarial worm

To better understand the relationship between Wolbachia and its worm host, adult Brugia pahangi were exposed to varying concentrations of doxycycline, minocycline, tetracycline and rifampicin and assessed for Wolbachia numbers and worm motility. Results showed that Wolbachia titers were significantly reduced at antibiotic concentrations that are at or slightly below the IC50s for worm motility in female worms (Fig. 1; Additional file 1: Fig. S1, Table S1). In contrast to these results, worms treated with higher concentrations of antibiotics had higher Wolbachia titers, i.e. as antibiotic concentrations increased there was a corresponding increase in Wolbachia titers (the Eagle effect). However, as the concentration of antibiotic increased, worms stopped moving and never recovered despite maintaining Wolbachia titers comparable to controls. Thus, worms were rendered moribund by the higher concentrations of antibiotics but Wolbachia persisted. The same trends in Wolbachia titers were observed when wsp copy numbers were analyzed both with and without normalization to worm gst copy numbers (Additional file 1: Fig. S2 and S3), indicating that changes in the wsp/gst ratio reflect changes in Wolbachia titer and were not driven by changes in gst copy number. Wolbachia titers in males treated with doxycycline, minocycline and rifampicin followed a similar pattern as observed in females with a positive correlation between Wolbachia titers and compound concentration (correlation coefficient of $r \geq 0.5$). Male worms treated with tetracycline, however, did not show a positive correlation between Wolbachia titers and compound concentration (Fig. 1; Additional file 1: Fig. S1 and S3, Table S1).

The motility-based IC50s for doxycycline, minocycline, tetracycline and rifampicin with female worms after 6 days in vitro were: 5.6, 3.6, 15.7 and 5.9 µM, respectively; for male worms, the IC50s for each of the antibiotics were 13.0, 10.9, 77.3 and 29.5 µM, respectively (Additional file 1: Fig. S1, Table S1).

Doxycycline and tetracycline inhibited worm motility without reducing Wolbachia titers in time course experiments

To further investigate the effects of antibiotics on female and male B. pahangi, both Wolbachia titers and worm motility at multiple antibiotic concentrations were assessed over time. These time course experiments showed that high concentrations of doxycycline and tetracycline did not reduce Wolbachia titers, though lower concentrations did; 100 µM doxycycline did not cause a significant decrease in Wolbachia titers in female worms at any time point compared to control worms, yet worm motility was inhibited by 90% on Day 1 and worms were moribund by Day 3 (99% 

...
### FEMALES

**Doxycycline**
- Motility IC₅₀: 5.6 μM
- R² = 0.82

| % Difference in wsp/gst Ratio | -69% | -81% | -79% | -70% | 2%  | 13% |
|-----------------------------|------|------|------|------|-----|-----|
| % Inhibition of Motility    | 28%  | 0%   | 2%   | 92%  | 100%| 99% |

**Minocycline**
- Motility IC₅₀: 3.6 μM
- R² = 0.64

| % Difference in wsp/gst Ratio | -78% | -79% | -81% | -81% | -17% | -14% |
|-----------------------------|------|------|------|------|------|------|
| % Inhibition of Motility    | 13%  | 41%  | 25%  | 69%  | 100% | 100% |

**Tetracycline**
- Motility IC₅₀: 15.7 μM
- R² = 0.44

| % Difference in wsp/gst Ratio | -67% | -80% | -71% | -81% | -74% | -7%  |
|-----------------------------|------|------|------|------|------|------|
| % Inhibition of Motility    | 0%   | 2%   | 0%   | 12%  | 56%  | 100% |

**Rifampicin**
- Motility IC₅₀: 5.9 μM
- R² = 0.59

| % Difference in wsp/gst Ratio | -78% | -76% | -40% | -11% | -12% | 41%  |
|-----------------------------|------|------|------|------|------|------|
| % Inhibition of Motility    | 30%  | 14%  | 20%  | 63%  | 99%  | 99%  |

### MALES

**Doxycycline**
- Motility IC₅₀: 13.0 μM
- R² = 0.97

| % Difference in wsp/gst Ratio | 3%   | -28% | -67% | -69% | 46%  | 116% |
|-----------------------------|------|------|------|------|------|------|
| % Inhibition of Motility    | 15%  | 0%   | 0%   | 19%  | 99%  | 99%  |

**Minocycline**
- Motility IC₅₀: 10.9 μM
- R² = 0.87

| % Difference in wsp/gst Ratio | -63% | -48% | -54% | -49% | -28% | -23% |
|-----------------------------|------|------|------|------|------|------|
| % Inhibition of Motility    | 23%  | 0%   | 0%   | 48%  | 85%  | 100% |

**Tetracycline**
- Motility IC₅₀: 77.3 μM
- R² = 0.83

| % Difference in wsp/gst Ratio | -2%  | -1%  | -32% | -77% | -72% | -42% |
|-----------------------------|------|------|------|------|------|------|
| % Inhibition of Motility    | 3%   | 8%   | 2%   | 0%   | 0%   | 76%  |

**Rifampicin**
- Motility IC₅₀: 29.5 μM
- R² = 0.96

| % Difference in wsp/gst Ratio | -83% | -64% | -42% | -60% | 52%  | 50%  |
|-----------------------------|------|------|------|------|------|------|
| % Inhibition of Motility    | 0%   | 0%   | 0%   | 0%   | 51%  | 100% |
Rifampicin reduced worm motility only at high concentrations but \textit{Wolbachia} titers were reduced at all concentrations in time course experiment

Rifampicin was also used in the time course experiment to assess the relationship between female and male worms and \textit{Wolbachia} titers (Fig. 2c; Additional file 1: Fig. S5, S8 and S9, Table S2). Each concentration of rifampicin tested reduced \textit{Wolbachia} titers but only the highest concentration inhibited motility. Worms treated with 100 \textmu M rifampicin were moribund by Day 6. Rifampicin reduced \textit{Wolbachia} titers at all concentrations starting as early as Day 1 for female worms and Day 3 for male worms. By Day 6 rifampicin reduced \textit{Wolbachia} titers by 50% or more compared to control worms at all concentrations. Figure 3 summarizes the effects that doxycycline, tetracycline and rifampicin have on worms (motility) and \textit{Wolbachia} numbers (% reduction) compared to control worms.

**Novel anti-\textit{Wolbachia} compounds show trends similar to approved antibiotics**

The novel quinazolines CBR417 and CBR490 were tested on \textit{B. pahangi} female worms in a 3-day assay (Fig. 4). Both CBR417 and CBR490 induced the Eagle effect in \textit{Wolbachia} titers, but as would be expected, inhibition of worm motility increased with compound concentration. Both compounds completely inhibited motility at 100 \textmu M. Treatment with 10 \textmu M CBR417 led to 72% inhibition of motility, while 10 \textmu M CBR490 also inhibited motility by 100%. Similar to doxycycline and tetracycline, \textit{Wolbachia} titers were not reduced even though worms were no longer motile at these concentrations. Conversely at the lowest concentration, 1 \textmu M, \textit{Wolbachia} titers were reduced by approximately 50% compared to the levels found in the controls but worms remained motile.

**Confocal microscopy confirms \textit{Wolbachia} reduction in the distal tip cell when exposed to antibiotic treatment**

Confocal microscopy of ovaries removed from worms treated with 10 \textmu M doxycycline, minocycline, tetracycline and rifampicin revealed that there were lower numbers of \textit{Wolbachia} in the distal tip region compared to those from worms in the control group. Figure 5 shows low and high magnification fluorescence images of fixed and stained untreated worms and worms treated with 10 \textmu M tetracycline and rifampicin. Tetracycline significantly reduced the number of \textit{Wolbachia} by 95% compared to the controls (\(P < 0.001\)); rifampicin also significantly reduced \textit{Wolbachia} by 83% (\(P < 0.05\)). Although doxycycline and minocycline had lower \textit{Wolbachia} titers (60 and 73%, respectively) compared to control worms, the reductions were not statistically significant.
Discussion
While testing known antibiotics and novel anti-*Wolbachia* compounds with *Brugia pahangi* adult worms *in vitro*, we observed a surprising pattern: *Wolbachia* killing occurred at low antibiotic concentrations but *Wolbachia* survived when treated with higher concentrations. The IC50 and time course experiments showed that high concentrations of antibiotics failed to clear *Wolbachia* from the adult *Brugia pahangi* worms, while low concentrations decreased *Wolbachia* titers. This phenomenon, known as the Eagle effect, was first described by Eagle [40], who found that *Staphylococcus aureus, Enterococcus faecalis* and group B and C *Streptococcus* survived penicillin treatment at concentrations above an optimal point. Since this initial report, the Eagle effect has been reported in numerous species of bacteria and

![Fig. 3](image-url) Illustration summarizing the Eagle effect on the endosymbiont *Wolbachia* in its worm host. The illustration depicts the worm and *Wolbachia* response to doxycycline, tetracycline and rifampicin. With doxycycline and tetracycline treatment worms become moribund at high concentration despite the high numbers of *Wolbachia*. Relative inhibition of worm motility is in blue (top), and relative changes in *Wolbachia* titers are in red (bottom). Worm motility is represented by the drawing of the worm: darker blue worms indicate more motility, and lighter blue worms indicate inhibited motility. *Wolbachia* titers are represented by red dots within the circle and are proportional to the *Wolbachia* titers normalized to controls.
fungi treated with antibiotics across multiple classes [41–43, 56], but to our knowledge this is the first case in which the Eagle effect occurs with the endosymbiont, \textit{Wolbachia}, in its worm host.
Although the underlying mechanisms that drive the Eagle effect are not known, investigators have suggested various possibilities to explain the increased survival of bacteria when treated with antibiotics at concentrations above the minimum inhibitory concentration (MIC), including antibiotic interference with bacterial autolytic enzymes, bacterial tolerance (bacteria transiently remain viable when exposed to high antibiotic concentrations) and the presence of non-replicating persister populations [42, 43]. In the Wolbachia endosymbiont/filarial worm relationship, it is possible that one or more of these mechanisms may be at play. Since Wolbachia are obligate intracellular bacteria, antibiotics must first pass through cells of the worm host to enter bacterial cells. It is possible that high concentrations of antibiotics such as doxycycline cause direct damage to host cells, which signal Wolbachia to initiate replication to maintain their population or to enter a protective, dormant “persister” state to reduce susceptibility to antibiotics. An analogous process occurs in adherent invasive Escherichia coli that are triggered to enter a persister state by the stressful conditions of the phagolysosome when phagocytosed by macrophages [57]. Lower antibiotic concentrations may be insufficient to cause damage to the worm cells, thus allowing the antibiotics to infiltrate the bacteria before signaling mechanisms can be engaged.

In an in vivo study by Gunderson et al. [39], Wolbachia titers were initially reduced following rifampicin treatment but then returned to normal levels 8 months later. They reported that populations of Wolbachia found within clusters were not reduced by antibiotic treatment, but that Wolbachia in the areas surrounding the clusters were eliminated, suggesting that these clusters contained Wolbachia in a protected state. It is possible that the clusters are affording protection for the Wolbachia and act as a privileged site in the worm that allows the bacteria to persist and contribute to the Eagle effect.

Given that worm motility was inhibited at high concentrations independently of Wolbachia killing, the antibiotics’ effect on worms was likely due to off-target effects. For instance, the tetracycline class of antibiotics (doxycycline, tetracycline, and minocycline) achieve their bacteriostatic effects by binding to the 30S ribosomal subunit, thereby inhibiting bacterial protein synthesis [58, 59], but they are also known to have effects on eukaryotic cells, e.g. inhibit mitochondrial function in both Wolbachia-infected and -uninfected Drosophila simulans [60], influence apoptosis [61, 62] and inhibit matrix metalloproteinases [63]. Brugia are known to have metalloproteinases that play important physiological roles, and the inhibition of these enzymes may play a role in worm killing [64]. These off-target drug effects may also affect worm survival when rifampicin is given at high concentrations in vitro. Rifampicin is known to induce reactive oxygen species (ROS) in bacteria [65, 66] in addition to inhibiting bacterial RNA polymerase. The mechanism of action is not yet known for the new quinazolines, CBR417 and CBR490, but these compounds resulted in findings similar to those of rifampicin in vivo. Animal studies have shown that these compounds decreased Wolbachia titers by 90–99% compared to vehicle controls [33, 36, 39], which suggests that worms recovered from treated animals may correspond to those worms that were exposed to low (1–10 µM) concentrations of antibiotics in the present in vitro study. Thus, worms recovered in vivo receive what may be the equivalent of low doses in vitro. However, further pharmacokinetic studies are needed to evaluate how in vitro results relate to in vivo studies.

Conclusions
Observation of the Eagle effect in Wolbachia suggests a common underlying mechanism that allows for diverse bacterial and fungal species to persist despite exposure to high concentrations of antimicrobial compounds. Further investigation into the Eagle effect in the Wolbachia-Brugia endosymbiotic relationship may shed light on conserved mechanisms by which bacteria evade antibiotic treatment and lead to improved treatments for both filarial and bacterial infections.

Fig. 5. Wolbachia were depleted in the distal tip region of worm ovaries. Worms were treated with 10 µM doxycycline, minocycline, tetracycline and rifampicin for 6 days. Negative controls contained 1% DMSO in culture media. a Graph shows medians with 95% confidence intervals. ****P < 0.001, *P < 0.05. b Images of the distal tip region of B. pahangi ovaries from worms treated in vitro with tetracycline and rifampicin showing the elimination of Wolbachia in worm ovaries. Panels on the right are high magnification images of the boxed regions in the distal tip region. Wolbachia are the red puncta stained with propidium iodide and DAPI; the nuclei of host cells (worm cells) in the ovaries are stained blue/magenta by DAPI.
a  \textit{Wolbachia} in distal tip of ovary

\begin{itemize}
\item Puncta per \text{\textmu}m$^2$
\item \textbf{DMSO, Doxycycline, Minocycline, Tetracycline, Rifampicin}
\end{itemize}

b  Tetracycline

- DMSO Control
- Antibiotic

Rifampicin

- DMSO Control
- Antibiotic
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13071-020-04545-w.

Additional file 1: Figure S1. IC_{50} of adult female and male worm motility on Day 6 of in vitro assays. Figure S2. Female IC_{50} wsp and gst copy numbers. Figure S3. Male IC_{50} wsp and gst copy numbers. Figure S4. Female doxycycline time course wsp and gst copy numbers. Figure S5. Male time course assay results. Figure S6. Male doxycycline time course wsp and gst copy numbers. Figure S7. Female tetracycline time course wsp and gst copy numbers. Figure S8. Female rifampicin time course wsp and gst copy numbers. Figure S9. Male rifampicin time course wsp and gst copy numbers. Table S1. Statistical significance of changes in wsp/gst ratios in IC_{50} assays. Table S2. Statistical significance of changes in wsp/gst ratios in time course assays.

Abbreviations
MDA: Mass drug administration; mf: Microfilariae; MTT: Thiazolyl blue tetrazolium bromide.

Acknowledgements
We thank Mona Luo for the illustration shown in Fig. 3 and Chris Franklin for his help with the graphics. We thank the Bill & Melinda Gates Foundation for financial support of this study. We also thank Calibr, a Division of The Scripps Research Institute, La Jolla, CA, USA, for providing CBR417 and CBR490. We especially thank Richard Spear for his generous gift to the Sullivan Laboratory. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors’ contributions
CAB, WS and JAS conceived the experiments; CAB, EG, LC, IV, BB performed experiments; CAB, LC, BS, WS, JAS wrote and reviewed the manuscript. All authors read and approved the final manuscript.

Funding
This work was funded by the Bill & Melinda Gates Foundation (award number OPP1017584).

Availability of data and materials
All data generated and analyzed during this study are included in this published article and its supplementary information files.

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA. 2 Department of Molecular, Cell and Developmental Biology, University of California, Santa Cruz, CA, USA. 3 Veterinary Pathobiology, University of Missouri-Columbia, Columbia, MO, USA. 4 Molecular Parasitology Division, New England Biolabs Inc, Ipswich, MA, USA.

Received: 4 August 2020 Accepted: 13 December 2020 Published online: 24 February 2021

References
1. Landmann F, Foster JM, Slatko B, Sullivan W. Asymmetric Wolbachia segregation during early Brugia malayi embryogenesis determines its distribution in adult host tissues. PLoS Negl Trop Dis. 2010;4:e758.

2. Taylor M, Hoerauf A. Wolbachia bacteria of filarial nematodes. Parasitol Today. 1999;15:437–42.

3. Hoerauf A, Volkmann L, Hamelmann C, Adjei O, Autenrieth IB, Fleischer B, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapeutic in filariasis. Lancet. 2000;355:1242–3.

4. Taylor MJ, Bandi C, Hoerauf A. Wolbachia bacterial endosymbionts of filarial nematodes. Adv Parasitol. 2005;60:245–84.

5. Slatko BE, Taylor MJ, Foster JM. The Wolbachia endosymbiont as an anti-filarial nematode target. Symbiosis. 2010;51:53–65.

6. Tamarozzi F, Halliday A, Gentili K, Hoerauf A, Pearlman E, Taylor MJ. Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment. Clin Microbiol Rev. 2011;24:459–68.

7. Bouchery T, Lefoulon E, Karadjian G, Nieguitsila A, Martin C. The symbiotic role of Wolbachia in Onchocercidae and its impact on filariasis. Clin Microbiol Infect. 2013;19:131–40.

8. Taylor MJ, Vonorin D, Johnston KL, Ford L. Wolbachia filarial interactions. Cell Microbiol. 2013;15:520–6.

9. Tamarozzi F, Turner JD, Pionnier N, Midgley A, Guimaraes AF, Johnston KL, et al. Wolbachia endosymbionts induce neutrophil extracellular trap formation in human onchocerciasis. Sci Rep. 2016;6:1–13.

10. Centers for Disease Control and Prevention. Progress toward elimination of Onchocerciasis in the Americas—1993–2012. Morb Mortal Wkly. 2013;62:405–8.

11. Richards F, Rizzo N, Espinoza CED, Monroy ZM, Valdez CCG, De Cabreira RM, et al. One hundred years after its discovery in Guatemala by Rodolfo Robles, Onchocerca volvulus transmission has been eliminated from the central endemic zone. Am J Trop Med Hyg. 2015;93:1295–304.

12. Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP. Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J. 2003;2:1–13.

13. Bockarie MJ, Taylor MJ, Gyapong JO. Current practices in the management of lymphatic filariasis. Expert Rev Anti Infect Ther. 2009;7:595–605.

14. McGarry HF, Pfarr K, Egerton G, Hoerauf A, Akue JP, Enyong P, et al. Evidence against Wolbachia symbiosis in Loa loa. Filaria J. 2003;2:9.

15. Boussinesq M, Fobi G, Kuesel AC. Alternative treatment strategies to accelerate the elimination of onchocerciasis. Int Heal. 2018;10:40–8.

16. Johnston KL, Ford L, Umaredy I, Townson S, Specht S, Pfarr K, et al. Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis. Int J Parasitol Drugs Drug Resist. 2014;4:278–86.

17. Clare RH, Cook DAN, Johnston KL, Ford L, Ward SA, Taylor MJ. Development and validation of a high-throughput anti-Wolbachia whole-cell screen: A route to macrofilaricidal drugs against onchocerciasis and lymphatic filariasis. J Biomed Screen. 2015;20:644–9.

18. Bakowski MA, McNamara CW. Advances in anti-filarial drug discovery for treatment of parasitic filarial worm infections. Trop Med Infect Dis. 2019;4:108.

19. Taylor MJ, Von Geldern TW, Ford L, Hubner MP, Marsh K, Johnston KL, et al. Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis. Sci Transl Med. 2019;11:1–11.

20. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A. Macrolarial activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet. 2005;365:2116–21.

21. Debrah AY, Mand S, Specht S, Marfo-Debrekyei Y, Batsa L, Pfarr K, et al. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog. 2006;2:e92.

22. Debrah AY, Mand S, Marfo-Debrekyei Y, Batsa L, Pfarr K, Buttnier M, et al. Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti. Trop Med Int Heal. 2007;12:1433–41.

23. Hoerauf A, Specht S, Buttnier M, Pfarr K, Mand S, Fimmers R, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol. 2008;197:335.

24. Hoerauf A, Specht S, Marfo-Debrekyei Y, Buttnier M, Debrah AY, Mand S, et al. Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus. Parasitol Res. 2009;104:437–47.
